Sign In
Buy VTGN
$0.229
-0.0108 (-4.50%)
At Close: Jul 17, 2026
VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update
04:25pm, Thursday, 12'th Aug 2021
PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan
VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
08:00am, Monday, 02'nd Aug 2021
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potentia
VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021
08:30am, Friday, 09'th Jul 2021
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potentia
VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors
08:30am, Wednesday, 07'th Jul 2021
Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders Ms. Rot
Are These 8 Penny Stocks to Watch on Your List Right Now?
05:03pm, Wednesday, 30'th Jun 2021
Making a penny stocks watchlist for 2021? Check these 8 out The post Are These 8 Penny Stocks to Watch on Your List Right Now?
VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2021 Results - Earnings Call Transcript
11:13pm, Tuesday, 29'th Jun 2021
VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q4 2021 Results - Earnings Call Transcript
VistaGen Therapeutics: Q4 Earnings Insights
05:36pm, Tuesday, 29'th Jun 2021
Shares of VistaGen Therapeutics (NASDAQ:VTGN) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 328.57% over the past year to ($0
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
04:15pm, Tuesday, 29'th Jun 2021
PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD)
8 Penny Stocks to Watch Right Now As June Comes to an End
06:40pm, Sunday, 27'th Jun 2021
Which penny stocks are investors watching as June comes to an end? The post 8 Penny Stocks to Watch Right Now As June Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information
SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the p
Sage Stock Declines on Late-Stage Depression Study Data
11:17am, Wednesday, 16'th Jun 2021
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
VistaGen Therapeutics Set to Join the Russell 2000® Index
08:00am, Wednesday, 16'th Jun 2021
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of
7 A-Rated Biotech Stocks to Buy Now
11:06am, Tuesday, 15'th Jun 2021
Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on Inv
5 Buy-Rated Stocks Trading Below $10 With Outstanding Upside Potential
06:05am, Saturday, 12'th Jun 2021
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
VistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94B
09:28am, Wednesday, 26'th May 2021
VistaGen Therapeutics Inc (NASDAQ: VTGN) has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Anxiety Disorder (SAD). PH94B is an odorless, rapid-onset, invest
